DEDHAM, Mass., Jan. 31 /PRNewswire/ -- Signet Laboratories, Inc., a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, today announced their conference schedule for 2006.
Signet representatives will showcase new products for clinical and research clients during major industry gatherings for both clinical pathology and neurodegenerative disease throughout the course of the year.
Signet will be attending the following Conferences in 2006: * United States and Canadian Academy of Pathology (USCAP)- February 13-15, Atlanta, GA * World Parkinson’s Conference - February 22-27, Washington DC * American Society for Neurochemistry - March 12-15, Portland, Oregon * American Association for Cancer Research (AACR) - April 1-5, Washington DC * Monoclonal Antibodies - April 28, Boston, MA * Transmissible Spongiform Encephalopathies - May 7-9, Baltimore, Maryland * International Conference on Alzheimer’s Disease and Related Disorders (ICAD) - July 15-20, Madrid, Spain * National Society For Histology (NSH) - September 9-14, Phoenix, Arizona * International Academy of Pathology (IAP) - September 17-21, Montreal, Canada * Society for Neuroscience (SFN) - October 14-18, Atlanta, Georgia * American College of Veterinary Pathologists (ACVP) - December 3-6, Tucson, Arizona
Throughout 2006, Signet also plans to attend nearly a dozen major university showcases and vendor shows, coordinated by Biotechnology Calendar and Life Science Exhibits, LLC.
About Signet Laboratories, Inc.
Signet Laboratories, Inc. (Dedham, MA) is a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease. Signet was created in 1989 as a commercial spinout of Johnson & Johnson’s Cambridge Research Laboratories, Inc.
The Company was founded to continue the mission originally established at CRL - the early detection and recurrence monitoring of patients with cancer and infectious disease. Signet has developed patented technology for diagnosis and recurrence monitoring and for risk assessment of asymptomatic patients in these areas. For more than a decade, the Company has aggressively maintained licensing and development programs, which are responsible for its broad patent and intellectual property estate.
Contact Information Company Contact Colleen Scott Signet Laboratories, Inc. 180 Rustcraft Road Dedham, MA 02026 Phone: 781.915.1404 Fax: 781.461.2456 cscott@signetlabs.com
Signet Laboratories, Inc.
CONTACT: Colleen Scott of Signet Laboratories, Inc., +1-781-915-1404,cscott@signetlabs.com
Web site: http://www.signetlabs.com/
